ClinicalTrials.gg
Active, not recruitingNCT03348280VDIMUpdated Dec 24, 2025

Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics

An observational study in Diabetes Mellitus, Type 2, Hypertension and Vitamin D Deficiency, sponsored by Washington University School of Medicine. Active, not recruiting at 2 sites in United States. Open to participants aged 25 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Washington University School of Medicine · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
40
Ages
25 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Diabetes Mellitus, Type 2 by Washington University School of Medicine — 2 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Washington University School of Medicine.

Started
2017
with 1 other
Observational
4 of 27
1 open now
Registered
22nd of 27
by date

Among the 27 studies in Diabetes Mellitus, Type 2 by Washington University School of Medicine, this one is one of 2 that started in 2017, is one of 4 observational ones, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies in Diabetes Mellitus, Type 2 by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 25 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Diabetes Mellitus, Type 2 by Washington University School of Medicine, or all of them as a file.
02

Study summary

This trial will evaluate whether a particular type of circulating white blood cell, monocytes, from type 2 diabetics with high blood pressure and vitamin D deficiency vs. sufficiency will induce hormones that increase blood pressure.

Read the detailed description

More than half of patients with type 2 diabetes mellitus develop hypertension, which doubles their risk for cardiovascular disease. Inflammation plays a role in the development of these diseases, and monocytes, a type of white blood cell, may be critical. This study will isolate monocytes from blood samples of patients with type 2 diabetes and high blood pressure who have either high levels of vitamin D or low levels of vitamin D, and determine what their effects are on stimulating production in kidney cells of a hormone that increases blood pressure.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Hypertension
  • Vitamin D Deficiency
04

Who can participate

Ages eligible
25 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

T2DM patients with hypertension

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes (T2DM)
  • Age: 25-80 years old
  • Vitamin 25(OH)D3 levels \<20 or >30 ng/ml.
  • : 5.5%-9.5%
  • Blood Pressure: \<160/100 mm Hg on BP lowering medications and
  • Blood Pressure: >120/80 to 160/100 mmHg without BP lowering medications

Exclusion criteria

Exclusion Criteria:

  • Recent weight loss of more than 5% within 3 months prior to screening
  • Current Pregnancy
  • Hypercalcemia
  • Previous heart attack and stroke
  • Heart failure
  • Atrial fibrillation
  • Heavy alcohol consumption
  • Extreme diets (Atkins, South Beach)
  • Chronic renal failure: stage 4 or worse
  • >2 + proteinuria on urine sample
  • Chronic diseases known to affect immunity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Vitamin D Deficient

    Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of \<20 ng/ml

    Diagnostic Test: Blood draw

  • Vitamin D Sufficient

    Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of \>30 ng/ml

    Diagnostic Test: Blood draw

Interventions

  • Diagnostic testBlood draw

    Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.

06

What researchers measure

Primary outcomes

  1. Renin production by monocytes

    Blood will be collected for isolation of monocytes. These cells will then be cultured to determine whether there is monocyte stimulation of a hormone that induces high blood pressure (renin) in kidney cells.

    Time frame: 2 weeks

Secondary outcomes

  1. Renin production by monocyte media

    Blood will be collected for isolation of monocytes. The media from these cells will then be added to culture to determine whether there is stimulation of a hormone that induces high blood pressure (renin) in kidney cells.

    Time frame: 2 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2017 (actual). Primary completion is estimated for Dec 2026, 111 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2017
First posted
Nov 20, 2017
StartActual
Sep 1, 2017
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03348280
Responsible party
Sponsor
First posted
Nov 20, 2017
Start date
Sep 1, 2017
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 24, 2025

Study contacts

Carlos Bernal-Mizrachi, MD
study director · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion